Scimitar Equity Research Issues Review on Physiometrix, Inc.

Scimitar Equity Research Issues Review on Physiometrix, Inc.



BOSTON, Nov. 8  /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar)
issued a review on Physiometrix, Inc. (NASDAQ:PHYX) entitled "Momentum and
Sales Drive Positive Q3 Revenues...Increasing Market Penetration." The analyst
research review is available on Scimitar's website;
http://www.scimitarequity.com/.

Scimitar Equity Research, Inc. provides unbiased research and insightful
analysis of the health sciences industry for the institutional and investment
communities. Scimitar does not own any securities related to the companies we
provide analysis or develop research products. We will not have investment
banking relationships with any company to maintain our independence and
objectivity. Investors are advised that this analysis and review is issued
solely for informational purposes and is not to be construed as an offer to
sell or the solicitation of an offer to buy. Scimitar was paid for preparing
this review. This analysis and review does not have regard to the specific
investment objectives, financial situation and the information contained herein
is based on sources that we believe to be reliable but is not guaranteed by us
as being accurate and does not purport to be a complete statement or summary of
the available data. Any opinions expressed are statements of our own judgment
as of the date of publication and are subject to change without notice.

  CONTACT:
   Scimitar Equity Research, Inc.
   Henry W. McCusker
   Director of Research
   phone: [phone]
   fax: [phone]
   e-mail: 

DATASOURCE: Scimitar Equity Research



CONTACT:  Henry W. McCusker, Director of Research of Scimitar Equity

Research, Inc., [phone], 



Web site:  http://www.scimitarequity.com/

Copyright